A Phase Ib Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders

Trial Profile

A Phase Ib Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Azacitidine (Primary) ; Eltrombopag (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms ELASTIC
  • Most Recent Events

    • 29 Mar 2016 Accrual to date is 18% according to United Kingdom Clinical Research Network record.
    • 27 Nov 2015 Planned End Date changed from 1 Aug 2015 to 30 Sep 2016 as reported by United Kingdom Clinical Research Network.
    • 01 Oct 2015 Accrual to date is 13% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top